SMi is thrilled to introduce the inaugural Alzheimer’s conference, taking place on 10th and 11th May 2016 in Central London, UK. The packed agenda features a mix of case study led presentations, panel debates, interactive workshops and keynote addresses that have been tailored for an audience of specialists in neuroscience, drug discovery and pathology, providing a focal point for the industry to discuss the latest therapeutic developments.

As more and more people live longer and the population ages, Alzheimer's has been identified as one of the biggest health problems in the 21st century. In the UK alone, a new report by the HSCIC has indicated that the number of patients being prescribed with drugs to treat Alzheimer’s has risen six-fold in the last 10 years. A 5 year strategy to fight dementia unveiled by the UK Government last year, reflects greater efforts to tackle the disease in the UK.

Alzheimer’s 2016 will hone in on early intervention strategies as well as solutions to on-going drug development challenges. It will strengthen knowledge in key topics such as; tau aggression; risk profiling; investment options; MRI imaging and biomarker evaluation, whilst looking at the practicalities of meaningful data from trials and keeping attendees at the forefront of clinical breakthroughs to adapt to the growing need for new treatments.

Understanding behavioural and psychiatric symptoms will be a major focus, as will hearing from a selection of pharmaceutical companies currently modelling disease progression. This will include case studies from Eli Lilly, Janssen Research & Development, GSK and Merck. An exclusive update on funding opportunities and academic drug discovery from Alzheimer’s Research UK, will be just one of the event highlights for 2016.

Key Speakers Include:

- Giulio Maria Pasinetti, Saunders Family Chair and Professor of Neurology, Icahn School of Medicine at Mount Sinai
- Luc Ver Donck, Scientific Director, Janssen Research & Development
- Steve Hood, Director, Biotransformation & Drug Disposition, GSK
- Matthew Kennedy, Director, Early Discovery Neuroscience, Merck
- Serge Van der Geyten, Director, Neuroscience External Affairs, Janssen Research & Development
- Michael J O’Neill, Head of Molecular Pathology Group, Eli Lilly
- Claude M Wischik, Executive Chairman, TauRx Therapeutics
- Simon Ridley, Director of Research, Alzheimer’s Research UK

Reasons to Attend:

- Gain new insights on the EU-wide EPAD and IMI projects to facilitate clinical trial designs and access to medical data
- Discuss the utility of data from imaging biomarkers and the clinical significance of endpoint outcomes
- Increase the likelihood of therapeutic success through strategic guidance on simultaneously targeting multiple pathogenic mechanisms
- Discover novel therapeutic strategies including Alzinova’s lead ARCC technology and oligomer-specific vaccine development
- Enable disease progression studies by revisiting endpoint outcomes in pre-dementia clinical trials
Further information and full speaker line-up is available online at http://www.alzheimers-conference.com/inderscience